QC

Cambridge Isotope Laboratories, Inc. (CIL) Announces Relocation of Corporate Headquarters and Expansion of Research & Development and cGMP Production

Retrieved on: 
Friday, March 15, 2024
CIL, GMP, CSO, QC, CGMP, Isotope, Research, Growth, API, Fine chemical

The new location is a two-building, 150,000-square-foot campus with 25 lakefront acres at 100 & 200 Ames Pond Drive.

Key Points: 
  • The new location is a two-building, 150,000-square-foot campus with 25 lakefront acres at 100 & 200 Ames Pond Drive.
  • The Ames Pond campus will be the home of a new 8,000-square-foot research and development (R&D) facility and will significantly expand cGMP, QC, formulations, and production labs.
  • This expansion provides CIL the space to develop new products and invest in advanced analytical and production technologies," states CIL's Chief Science Officer (CSO) Todd Osiek.
  • CIL will continue operating its existing headquarters at 3 Highwood Drive, Tewksbury, MA, and production facility located 50 Frontage Road in Andover, MA.

4BIO Capital Portfolio Company Ascend Acquires Florida-Based GMP Manufacturing Capacity

Retrieved on: 
Tuesday, April 9, 2024
Retina, AAV, QC, Partnership, Patient, Research, Acquisition, CMC, Protein, GMP, Investment, Therapy, San Francisco Bay Area, Retinitis pigmentosa, Pharmaceutical industry

London, UK, 9 April 2024 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies, today announces that its portfolio company, Ascend Advanced Therapies (Ascend), an end-to-end gene therapy development partner, has acquired the Contract, Manufacturing and Controls (CMC) team and site in Alachua, Florida, from Beacon Therapeutics (Beacon).

Key Points: 
  • London, UK, 9 April 2024 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies, today announces that its portfolio company, Ascend Advanced Therapies (Ascend), an end-to-end gene therapy development partner, has acquired the Contract, Manufacturing and Controls (CMC) team and site in Alachua, Florida, from Beacon Therapeutics (Beacon).
  • The transaction brings an operational good manufacturing practice (GMP) facility, process and analytical development capabilities, and additional experts to the Ascend team.
  • This key acquisition brings Ascend its first US manufacturing site, a huge milestone for the Company.
  • The facility is highly synergistic to a growing global network of Ascend sites that has been built via critical acquisitions.

Rogers $1M Season of Canada’s Got Talent: Top Performances from Tonight’s Episode on Citytv

Retrieved on: 
Wednesday, April 3, 2024
QC, CIBC, Head, BALL, HEAD, Toronto Maple Leafs, Magic, Glass, Wine, CGT, Lilly, AIR, TROY, Singing, MICHAEL

DANIEL POWTER (Vernon, BC) surprised the audience by singing “Bad Day,” an original song he wrote that topped the charts for several weeks in 2005.

Key Points: 
  • DANIEL POWTER (Vernon, BC) surprised the audience by singing “Bad Day,” an original song he wrote that topped the charts for several weeks in 2005.
  • MITCHELL HRYCAN (Saskatoon, SK) duped the judges when his twin, MICHAEL HRYCAN, surprised the crowd in a shocking twist!
  • Together with Canada’s Got Talent, Rogers is committed to investing in premium original Canadian content while fostering homegrown talent.
  • Last year, Rogers contributed approximately $950M to Canadian content and produced over 12,700 hours of unique Canadian programming.

Valleyfield-based Liquiteck acquired by Eastern Canada’s largest industrial process automation supplier, Laurentide Controls

Retrieved on: 
Tuesday, April 2, 2024
Automation, QC, Organization, Laurentide Ice Sheet, Acquisition, Video game

KIRKLAND, Quebec, April 02, 2024 (GLOBE NEWSWIRE) -- Laurentide Controls, the largest supplier of industrial process automation solutions in Eastern Canada, announced today the acquisition of Liquiteck, a prominent industrial pump distributor.

Key Points: 
  • KIRKLAND, Quebec, April 02, 2024 (GLOBE NEWSWIRE) -- Laurentide Controls, the largest supplier of industrial process automation solutions in Eastern Canada, announced today the acquisition of Liquiteck, a prominent industrial pump distributor.
  • This acquisition represents the latest step in Laurentide’s growth, consolidating its position as a major player in the changing industrial ecosystem.
  • As the Emerson Impact Partner for its territory, Laurentide’s core offering consists of process valves, instrumentation, process automation software and industrial reliability solutions including training.
  • Liquiteck specializes in pumps, system design, and pump repairs, serving heavy industry, commercial and municipal clients.

Westland Insurance Group announces new Quebec brand Globalex Assurances

Retrieved on: 
Monday, April 1, 2024
Professional, QC, Culture, Acquisition, Insurance, Financial adviser

MONTREAL, QC, April 01, 2024 (GLOBE NEWSWIRE) -- Westland Insurance is pleased to announce the launch of its Quebec brand Globalex Assurances (“Globalex”).

Key Points: 
  • MONTREAL, QC, April 01, 2024 (GLOBE NEWSWIRE) -- Westland Insurance is pleased to announce the launch of its Quebec brand Globalex Assurances (“Globalex”).
  • By having a dedicated brand for the region, Globalex can better address the specific expectations of its Quebec clients.
  • Westland Insurance entered the Quebec market in January 2021 and since then has welcomed several Quebec brokerages to the Westland Insurance Group, including three prominent brokerages: Axxium Assurance, Assurances R. Legault, and Niche Assurance.
  • "We’re excited to introduce the Globalex Assurances brand to Quebec," said Jamie Lyons, President & CEO of Westland Insurance.

M1 Composites Technology Becomes Preferred A220 Repair Center

Retrieved on: 
Tuesday, April 9, 2024
QC, Airbus, A220, Satair, Engineering, Airline

LAVAL, QC, April 9, 2024 /PRNewswire/ - M1 Composites Technology Inc, a leading Quebec-based aerostructure engineering, manufacturing, and sustainment/repair company has been selected by Satair, an Airbus Services company, as the preferred North American repair station for Airbus A220  aircraft flight controls and structural parts.

Key Points: 
  • LAVAL, QC, April 9, 2024 /PRNewswire/ - M1 Composites Technology Inc, a leading Quebec-based aerostructure engineering, manufacturing, and sustainment/repair company has been selected by Satair, an Airbus Services company, as the preferred North American repair station for Airbus A220  aircraft flight controls and structural parts.
  • Based in Laval, M1 Composites competed against several large and well-established engineering & repair companies for this contract, which is expected to generate new jobs for the 100-person company.
  • As the North American preferred repair station, M1 Composites will ensure these operators have access to reliable and efficient aerostructure maintenance solutions.
  • Given the integrated aerospace supply chain that exists between both Canada and the U.S., M1 Composites is well-positioned to aid operators in the region with repair solutions on aero structure.

Hudson's Bay Foundation and the Gord Downie & Chanie Wenjack Fund Announce First Recipients of Oshki Wupoowane | The Blanket Fund's Capacity Building Grant

Retrieved on: 
Tuesday, April 9, 2024
QC, Organization, Growth, Partnership, History, Sale, Truth, Capacity building, Organic, Capacity, Gord Downie, Blanket

TORONTO, April 9, 2024 /CNW/ - Hudson's Bay Foundation and the Gord Downie & Chanie Wenjack Fund are pleased to announce the first round of grant recipients of Oshki Wupoowane | The Blanket Fund's Capacity Building Grant.

Key Points: 
  • TORONTO, April 9, 2024 /CNW/ - Hudson's Bay Foundation and the Gord Downie & Chanie Wenjack Fund are pleased to announce the first round of grant recipients of Oshki Wupoowane | The Blanket Fund's Capacity Building Grant.
  • The recipients of the first round of Capacity Building funding through Oshki Wupoowane | The Blanket Fund are:
    Community Arts Mentorship Program (C.A.M.P.
  • "We're excited to announce the first recipients of Oshki Wupoowane | The Blanket Fund Capacity Building Grant," said Sarah Midanik, President & CEO, Gord Downie & Chanie Wenjack Fund.
  • The Gord Downie & Chanie Wenjack Fund looks forward to collaborating with these organizations in the years ahead on our ongoing journey of reconciliation.

Waters Launches Alliance iS Bio HPLC System to Help Biopharma QC Labs Increase Efficiency and Reduce Errors

Retrieved on: 
Tuesday, April 9, 2024
QA/QC, QC, WAT, Intelligence, HPLC, Laboratory, HPS, Waters Corporation

MILFORD, Mass., and MUNICH, April 9, 2024 /PRNewswire/ -- Analytica 2024 -- Waters Corporation (NYSE:WAT) today announced the launch of the Alliance iS Bio HPLC System with new capabilities that address the operational and analytical challenges of biopharma quality control (QC) laboratories. The new HPLC system combines advanced bio-separation technology and built-in instrument intelligence features. It is designed to help biopharma QC analysts boost efficiency and eliminate up to 40% of common errors, saving time lost by investigating the source of failed runs and out-of-specification results.

Key Points: 
  • New Alliance™ iS Bio High Performance Liquid Chromatography (HPLC) System helps biopharmaceutical QC laboratories boost efficiency and eliminate up to 40% of common errorsi.
  • MILFORD, Mass., and MUNICH, April 9, 2024 /PRNewswire/ -- Analytica 2024 -- Waters Corporation (NYSE:WAT) today announced the launch of the Alliance iS Bio HPLC System with new capabilities that address the operational and analytical challenges of biopharma quality control (QC) laboratories.
  • The Alliance iS Bio HPLC System also combines with Waters compliance-ready Empower Chromatography Software to help laboratories collect, manage, and report chromatography test results.
  • It integrates seamlessly with Waters and third-party liquid chromatography instruments to help high-volume QC labs manage operational risk, mitigate disruptions, and increase overall productivity.

Waters Launches Alliance iS Bio HPLC System to Help Biopharma QC Labs Increase Efficiency and Reduce Errors

Retrieved on: 
Tuesday, April 9, 2024
QA/QC, QC, WAT, Intelligence, HPLC, Laboratory, HPS, Waters Corporation

MILFORD, Mass., and MUNICH, April 9, 2024 /PRNewswire/ -- Analytica 2024 -- Waters Corporation (NYSE:WAT) today announced the launch of the Alliance iS Bio HPLC System with new capabilities that address the operational and analytical challenges of biopharma quality control (QC) laboratories. The new HPLC system combines advanced bio-separation technology and built-in instrument intelligence features. It is designed to help biopharma QC analysts boost efficiency and eliminate up to 40% of common errors, saving time lost by investigating the source of failed runs and out-of-specification results.

Key Points: 
  • New Alliance™ iS Bio High Performance Liquid Chromatography (HPLC) System helps biopharmaceutical QC laboratories boost efficiency and eliminate up to 40% of common errorsi.
  • MILFORD, Mass., and MUNICH, April 9, 2024 /PRNewswire/ -- Analytica 2024 -- Waters Corporation (NYSE:WAT) today announced the launch of the Alliance iS Bio HPLC System with new capabilities that address the operational and analytical challenges of biopharma quality control (QC) laboratories.
  • The Alliance iS Bio HPLC System also combines with Waters compliance-ready Empower Chromatography Software to help laboratories collect, manage, and report chromatography test results.
  • It integrates seamlessly with Waters and third-party liquid chromatography instruments to help high-volume QC labs manage operational risk, mitigate disruptions, and increase overall productivity.

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Ovarian cancer, Head, Uterine cancer, GSK, Patient, Dendreon, Commercial, Cancer, Bristol Myers Squibb, Neoplasm, Melanoma, TCR, Therapy, Research, MAGEA4, Sarcoma, GMP, Safety, Pharmacokinetics, Amgen, QC, CDMO, Development, Prevalence, Half-life, RECIST, Senior, FDA, Lung cancer, Administration, Conference, Entrepreneurship, Bank, Corr, Messenger, Protein, Pharmacology, Uveal melanoma, Pharmaceutical industry

“Immatics kicked off 2024 with a successful capital raise, providing significant financial runway and additional momentum to advance our ongoing clinical cell therapy and bispecific trials,” said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics.

Key Points: 
  • “Immatics kicked off 2024 with a successful capital raise, providing significant financial runway and additional momentum to advance our ongoing clinical cell therapy and bispecific trials,” said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics.
  • For IMA203CD8 GEN2, Immatics cleared dose level 4a (DL4a, up to ~1.6x109 TCR-T cells) in December 2023, which is currently intended to be the target dose for further development.
  • A next data update for both Phase 1b cohorts with IMA203 GEN1 and IMA203CD8 GEN2 is planned for 2H 2024.
  • On September 11, 2023, Immatics announced a strategic multi-platform collaboration with Moderna, combining Immatics’ target and TCR platforms with Moderna’s cutting-edge mRNA technology.